Our top pick for
EverQuote, Inc is an internet content & information business based in the US. EverQuote shares (EVER) are listed on the NASDAQ and all prices are listed in US Dollars. EverQuote employs 425 staff and has a trailing 12-month revenue of around USD$346.9 million.
|52-week range||USD$21.001 - USD$63.44|
|50-day moving average||USD$44.0933|
|200-day moving average||USD$39.5562|
|Wall St. target price||USD$61.58|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.678|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Revenue TTM||USD$346.9 million|
|Gross profit TTM||USD$325.6 million|
|Return on assets TTM||-4.66%|
|Return on equity TTM||-18.83%|
|Market capitalisation||USD$1.4 billion|
TTM: trailing 12 months
There are currently 2.6 million EverQuote shares held short by investors – that's known as EverQuote's "short interest". This figure is 17% down from 3.1 million last month.
There are a few different ways that this level of interest in shorting EverQuote shares can be evaluated.
EverQuote's "short interest ratio" (SIR) is the quantity of EverQuote shares currently shorted divided by the average quantity of EverQuote shares traded daily (recently around 314584.09371147). EverQuote's SIR currently stands at 8.11. In other words for every 100,000 EverQuote shares traded daily on the market, roughly 8110 shares are currently held short.
However EverQuote's short interest can also be evaluated against the total number of EverQuote shares, or, against the total number of tradable EverQuote shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case EverQuote's short interest could be expressed as 0.09% of the outstanding shares (for every 100,000 EverQuote shares in existence, roughly 90 shares are currently held short) or 0.1438% of the tradable shares (for every 100,000 tradable EverQuote shares, roughly 144 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against EverQuote.
Find out more about how you can short EverQuote stock.
We're not expecting EverQuote to pay a dividend over the next 12 months.
Over the last 12 months, EverQuote's shares have ranged in value from as little as $21.001 up to $63.44. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while EverQuote's is 1.5252. This would suggest that EverQuote's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
EverQuote, Inc. operates an online marketplace for insurance shopping in the United States. Its online marketplace offers consumers shopping for auto, home and renters, life, health, and commercial insurance. The company serves carriers, agents, and indirect distributors and aggregators. The company was formerly known as AdHarmonics, Inc., and changed its name to EverQuote, Inc. in November 2014. EverQuote, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.